EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current State of Human Gene Therapy: Approved Products and Vectors

Aladdin Y Shchaslyvyi iD, Svitlana V Antonenko, Maksym G Tesliuk, Gennadiy D Telegeev

Pharmaceuticals · 05.10.2023 · 16 (10) · 1416

DOI: 10.3390/ph16101416 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 05.10.2023. Verfasst von Aladdin Y Shchaslyvyi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Biology and Genetics, National Academy of Sciences of Ukraine, 150, Zabolotnogo Str., 03143 Kyiv, Ukraine. Die Arbeit wurde bisher 119-mal zitiert (Crossref) und nennt 231 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the realm of gene therapy, a pivotal moment arrived with Paul Berg’s groundbreaking identification of the first recombinant DNA in 1972. This achievement set the stage for future breakthroughs. Conditions once considered undefeatable, like melanoma, pancreatic cancer, and a host of other ailments, are now being addressed at their root cause—the genetic level. Presently, the gene therapy landscape stands adorned with 22 approved in vivo and ex vivo products, including IMLYGIC, LUXTURNA, Zolgensma, Spinraza, Patisiran, and many more. In this comprehensive exploration, we delve into a rich assortment of 16 drugs, from siRNA, miRNA, and CRISPR/Cas9 to DNA aptamers and TRAIL/APO2L, as well as 46 carriers, from AAV, AdV, LNPs, and exosomes to naked mRNA, sonoporation, and magnetofection. The article also discusses the advantages and disadvantages of each product and vector type, as well as the current challenges faced in the practical use of gene therapy and its future potential.

Schlagwörter

Stichwörter der Autor:innen

gene therapy drugshuman gene therapyhuman gene therapy productsnon-viral vectorsphysical delivery methodsviral vectors

Autor:innen und Institutionen

  • Institute of Molecular Biology and Genetics, National Academy of Sciences of Ukraine, 150, Zabolotnogo Str., 03143 Kyiv, Ukraine.

ORCID-Profile: Aladdin Y Shchaslyvyi

Zitieren

APA

Shchaslyvyi, A. Y., Antonenko, S. V., Tesliuk, M. G., & Telegeev, G. D. (2023). Current State of Human Gene Therapy: Approved Products and Vectors. Pharmaceuticals, 16(10), 1416. https://doi.org/10.3390/ph16101416

Vancouver

Shchaslyvyi AY, Antonenko SV, Tesliuk MG, Telegeev GD. Current State of Human Gene Therapy: Approved Products and Vectors. Pharmaceuticals. 2023;16(10):1416. doi:10.3390/ph16101416

BibTeX
@article{Shchaslyvyi2023,
  author = {Shchaslyvyi, Aladdin Y and Antonenko, Svitlana V and Tesliuk, Maksym G and Telegeev, Gennadiy D},
  title = {Current State of Human Gene Therapy: Approved Products and Vectors},
  journal = {Pharmaceuticals},
  year = {2023},
  volume = {16},
  number = {10},
  pages = {1416},
  doi = {10.3390/ph16101416}
}
Kostenlos starten →